Thyroid Function Tests: TSH, T3, and T4

Thyroid function tests are a panel of blood-based measurements used to assess how well the thyroid gland is producing and regulating hormones. The three primary markers — thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4) — each reflect a distinct point in the hypothalamic-pituitary-thyroid axis. Understanding what these values measure, how they interact, and what their reference ranges signify is foundational to diagnosing and managing conditions such as hypothyroidism and hyperthyroidism and Graves' disease.

Definition and Scope

Thyroid function testing encompasses a structured set of assays that measure hormone concentrations in venous blood. The U.S. Food and Drug Administration (FDA) classifies thyroid hormone immunoassays as Class II medical devices under 21 CFR Part 866, subject to performance standards that govern laboratory accuracy and precision.

The three core analytes are defined as follows:

  1. TSH (Thyroid-Stimulating Hormone): A glycoprotein secreted by the anterior pituitary gland that stimulates thyroid hormone synthesis. TSH is the most sensitive first-line marker for thyroid dysfunction. The American Thyroid Association (ATA) identifies a reference range of approximately 0.5 to 4.5 mIU/L for most non-pregnant adults, though laboratory-specific reference intervals vary (ATA clinical guidelines).
  2. Total T4 and Free T4 (Thyroxine): T4 is the predominant hormone secreted by the thyroid gland. Free T4 (FT4) measures the unbound, biologically active fraction and is preferred over total T4 in most clinical panels because total T4 is affected by protein-binding changes.
  3. Total T3 and Free T3 (Triiodothyronine): T3 is the metabolically active hormone; approximately 80% is produced peripherally by deiodination of T4. Free T3 (FT3) measurement is reserved for specific clinical contexts such as suspected T3 toxicosis or monitoring of thyroid cancer therapy.

The broader landscape of blood tests for endocrine conditions situates thyroid panels within a wider framework that includes adrenal, pituitary, and metabolic markers.

How It Works

The hypothalamic-pituitary-thyroid (HPT) axis operates as a closed-loop feedback system. The hypothalamus releases thyrotropin-releasing hormone (TRH), which signals the anterior pituitary to secrete TSH. TSH then binds to receptors on thyroid follicular cells, stimulating synthesis and release of T4 and T3. Elevated circulating thyroid hormone levels suppress TSH output; low levels trigger increased TSH secretion.

This inverse relationship explains why TSH serves as the primary screening tool:

Laboratory measurement relies on immunoassay technology. Third-generation TSH assays achieve a functional sensitivity of approximately 0.01 mIU/L, enabling detection of subtle suppression that earlier assays could not reliably distinguish from zero (National Academy of Clinical Biochemistry [NACB] Laboratory Medicine Practice Guidelines, Thyroid Disease). Free T4 is typically measured by equilibrium dialysis or analog immunoassay; the former is the reference method per College of American Pathologists (CAP) proficiency standards.

Specimen requirements are standardized: TSH and free hormone measurements use serum or plasma from a standard venipuncture. No fasting is required, though timing relative to thyroid hormone replacement doses matters — patients taking thyroid hormone replacement should have blood drawn before their morning dose to avoid transient post-absorption peaks in FT4.

Common Scenarios

Thyroid function panels are ordered across a range of clinical presentations. The most frequently encountered patterns include:

Screening in asymptomatic adults: The U.S. Preventive Services Task Force (USPSTF) does not recommend routine thyroid screening in asymptomatic non-pregnant adults as of its 2015 evidence review, citing insufficient evidence of net benefit. Despite this, TSH is frequently ordered as part of general metabolic workup for fatigue, weight change, or cardiovascular risk assessment.

Pregnancy: The ATA recommends TSH screening in the first trimester for women at elevated risk. TSH reference ranges shift during pregnancy — the upper limit drops to approximately 2.5 mIU/L in the first trimester due to the thyroid-stimulating effects of human chorionic gonadotropin (hCG). This is covered in detail within the topic of pregnancy and endocrine conditions.

Thyroid nodules and cancer monitoring: After thyroid surgery or radioactive iodine ablation for differentiated thyroid cancer, TSH suppression therapy targets TSH below 0.1 mIU/L in high-risk patients to reduce recurrence risk. Thyroglobulin measurement is added to the panel in this context. More detail on diagnostic workup appears at thyroid ultrasound and biopsy.

Subclinical dysfunction: Subclinical hypothyroidism is defined as an elevated TSH with a normal free T4, while subclinical hyperthyroidism features a suppressed TSH with normal free T4 and T3. Both categories require interpretation within the clinical context documented by the treating provider.

Decision Boundaries

Interpreting thyroid function tests requires matching numerical results against pre-specified decision thresholds. The following boundaries guide clinical reasoning, as described in ATA and Endocrine Society published guidelines:

Pattern TSH Free T4 Free T3 Interpretation
Overt hypothyroidism >10 mIU/L Low Low/normal Primary thyroid failure
Subclinical hypothyroidism 4.5–10 mIU/L Normal Normal Early or mild thyroid underfunction
Overt hyperthyroidism <0.01 mIU/L High High Thyroid overproduction
Subclinical hyperthyroidism 0.01–0.5 mIU/L Normal Normal Mild excess, risk stratification needed
T3 toxicosis Low Normal High Disproportionate T3 production
Central hypothyroidism Low or normal Low Low Pituitary/hypothalamic failure

The regulatory context for endocrinology encompasses the laboratory oversight frameworks — including CLIA 88 (Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. §263a) — that govern acceptable analytical performance for thyroid assays performed in certified laboratories.

The endocrinologyauthority.com home page situates thyroid function testing within the full scope of endocrine diagnostic practice, from diabetes to adrenal and pituitary disorders.

Interference from biotin (vitamin B7) supplementation is a documented confound: doses exceeding 5 mg/day can falsely suppress TSH and falsely elevate free T4 in biotin-streptavidin-based immunoassays, according to the FDA Safety Communication issued in November 2017. Patients are advised by their providers to discontinue biotin supplements at least 48 hours before blood draw.

Thyroid peroxidase antibodies (TPO-Ab) and thyroglobulin antibodies (TG-Ab) are not direct measures of thyroid function but are added when autoimmune thyroid disease — such as Hashimoto's thyroiditis or Graves' disease — is under investigation, as their presence can affect assay accuracy and management decisions.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)